🟢 Connect Biopharma is trading 9.61% up in pre-market with no clear catalyst identified

Connect Biopharma is trading at $2.02, up 9.61%, in pre-market with no clear company-specific catalyst identified.

• No new company-specific announcement dated September 8, 2026 was identified; Phase 2 Seabreeze STAT asthma and COPD topline results were expected in September 2026, offering a potential near-term clinical catalyst.
• Connect Biopharma also announced a September 15, 2026 H.C. Wainwright presentation, which does not directly explain the move. Broader markets were weaker, so the gain was not market-driven.